Nanexa

Nanexa Forward P/E

The Forward P/E Ratio of Nanexa (NANEXA.ST) as of Oct 23, 2026 is -50.86. In the previous year, Forward P/E Ratio was -23.26 — a change of 118.70% (lower).

Forward P/E

-50.86

YoY

118.70%

Last updated:

Forward P/E Ratio of Nanexa is 2025 -50.86 . Forward P/E Ratio of Nanexa was 2024 -23.26 . It decreases by 118.70% lower compared to the previous year.

The Nanexa Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2018
-51.85 SEK
Jan 1, 2019
-44.72 SEK
Jan 1, 2020
-26.65 SEK
Jan 1, 2021
-16.09 SEK
Jan 1, 2022
-9.89 SEK
Jan 1, 2023
-7.58 SEK
Jan 1, 2024
-23.26 SEK
Jan 1, 2025
-50.86 SEK
The Nanexa Forward P/E history
YEARForward P/EYoY
-50.86+118.70%
-23.26+206.76%
-7.58-23.33%
-9.89-38.54%
-16.09-39.62%
-26.65-40.42%
-44.72-13.75%
-51.85-28.63%
-72.66-20.35%
-91.22-35.01%
-140.37-77.51%
-624.10—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nanexa Stock analysis

What does Nanexa do? Nanexa AB develops and distributes medical nanotechnology products including PharmaShell, a drug delivery system for targeted dosing, and antifungal coating that protects medical products from fungal growth. The company also offers low-friction coating for peripheral venous catheters. Its products are sold to healthcare providers and medical device manufacturers seeking advanced solutions for drug delivery and infection prevention. Nanexa AB's revenue comes from the sale of its nanotechnology-based products to healthcare institutions and medical device companies. The firm focuses on life science R&D, targeting applications in pharmaceuticals and medical device manufacturing. Its product portfolio serves the healthcare sector by enhancing drug efficacy and protecting medical equipment from microbial contamination. The company's business model relies on selling specialized coatings and delivery systems to medical professionals and manufacturers. PharmaShell enables precise drug targeting, while antifungal and low-friction coatings address specific clinical needs in medical device usage. These products are designed to improve patient outcomes and reduce complications in medical treatments. Nanexa is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nanexa stock

Forward P/E Ratio of Nanexa is -50.86 in 2025.

Forward P/E Ratio of Nanexa changed from -23.26 to -50.86, representing a 118.70% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Nanexa since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Nanexa with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Nanexa

All Key Metrics — Nanexa